For many years, Creative Bioarray has been working on disease modeling using human iPSC and has made great progress. We focus on chimeric models to help our clients gain insight into the pathogenesis of multiple diseases and discover new therapeutic approaches.
iPSC for Modeling Chimaeric Disease
Organoid-based disease models are restricted to the tissue culture environment, which hinders researchers from analyzing the interactions with the circulatory, hormones and other metabolic mediators, nervous and immune systems that are present in vivo. In addition, organoids are largely dependent on self-organization in culture and lack many of the morphogenetic cues present in vivo. For example, when modeling blood disorders, niche factors are rarely incorporated by in vitro differentiation systems into the specification of hematopoietic differentiation and bona fide hematopoietic stem cells. In recent years, several studies have reported advances in the xenografts of cells and organoids differentiated from human PSCs, which address the limitations of organoid-based disease models.
iPSC-based chimeric disease modeling via xenografts has been shown to accelerate the development of cellular therapies by faithfully mimicking human diseases. Multiple reports on the current status of human iPSC chimeric models have illustrated the diversity of tissues and organs that have been modeled as chimeras and the multiple disease classes modeled in chimeras. In conclusion, the progress of disease modeling using human iPSC has largely promoted the development of new therapies for the treatment of a variety of diseases.
Fig.1 iPSC-based chimaeric models. (Rowe, 2019)
Our Solutions
To help customers develop iPSC-based chimeric models, we offer the following solutions:
- Haematopoietic chimeras
- Chimeras for model Mimicry
- Neural chimaeras
- Solid Organ Chimeras
- Modeling adoptive immunity
We improved the ability for in vivo engraftment in haematopoietic stem and progenitor cells (HSPCs) derived via directed differentiation from PSCs to improve disease models and advance iPSC-based hematopoietic therapies.
Xenografting tumors into immunodeficient mouse models is a critical technique in cancer research. We have used iPSC-derived organoids and xenografted them into mice to provide new insights into the development and progression of solid tumors.
We help our clients develop the value of chimeric models in simulating human neurological diseases with iPSCs. For example, we have improved the function of Parkinson's disease models by implanting dopaminergic neurons derived from human or non-human primate iPSCs into the brains of rats.
We have transplanted human iPSC-derived organoids into mice to incorporate the vascular system and interact with normal host physiology. For example, we helped our clients transplant human iPSC-derived beta cells into the mouse pancreas with the secretion of human insulin.
We help our clients develop applications for human iPSC in modeling adoptive T-cell therapy in cancer and infectious disease.
Advantages
- Professional research team
- Advanced cell reprogramming technologies
- Strict quality control and detailed after-sales service
- Highly flexible solutions
With many years of service experience in the field of cell reprogramming, Creative Bioarray provides customers with a variety of scientific solutions for establishing chimaeric disease models based on iPSC. If you need our scientific assistance, please contact us directly.
Reference
- Rowe, R.G.; Daley, G.Q. Induced pluripotent stem cells in disease modelling and drug discovery. Nat Rev Genet. 2019, 20(7): 377-388.